Dana-Farber Cancer Institute: Melanoma trials

The registry lists 23 Melanoma studies with Dana-Farber Cancer Institute as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 12Phase 2 11No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain MetsTerminatedNCT04899921Phase 2Results posted
• Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaActive, not recruitingNCT03929029Phase 1Results posted
• MCS110 With BRAF/MEK Inhibition in Patients With MelanomaCompletedNCT03455764Phase 1/2Results posted
• Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorCompletedNCT03239145Phase 1Results posted
• LY3022855 With BRAF/MEK Inhibition in Patients With MelanomaCompletedNCT03101254Phase 1/2Results posted
• STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV MelanomaTerminatedNCT01551693Phase 2Results posted
• STA-9090(Ganetespib) in Metastatic Ocular MelanomaCompletedNCT01200238Phase 2Results posted
• Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged MelanomaCompletedNCT00788775Phase 2Results posted
• SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous MelanomaCompletedNCT00577382Phase 2Results posted
• Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2WithdrawnNCT05482074Phase 2
• Video Education With Result Dependent dIsclosureCompletedNCT05225428Not applicable
• NeoVax + CDX-301 and Nivolumab or Pembrolizumab in MelanomaActive, not recruitingNCT04930783Phase 1
• Sargramostim (GM-CSF) + PD-1WithdrawnNCT04703426Phase 2
• A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV MelanomaWithdrawnNCT04007588Phase 2
• A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer CareActive, not recruitingNCT02279004
• Dendritic Cell Activating Scaffold in MelanomaCompletedNCT01753089Phase 1
• NIR-Guided Sentinel Lymph Node Mapping in MelanomaCompletedNCT01121718Phase 1
• Panobinostat (LBH589) in Patients With Metastatic MelanomaCompletedNCT01065467Phase 1
• Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)CompletedNCT00809588Phase 1
• Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV MelanomaCompletedNCT00790010Phase 1
• Adoptive Transfer of MART1/Melan-A CTL for Malignant MelanomaCompletedNCT00512889Phase 1
• Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV MelanomaCompletedNCT00258687Phase 1
• Vaccine Therapy in Treating Patients With Stage III or Stage IV MelanomaStatus unknownNCT00085397Phase 2